Previous Article | Next Article 
Molecular and Cellular Biology, August 2001, p. 5396-5407, Vol. 21, No. 16
0270-7306/01/$04.00+0 DOI: 10.1128/MCB.21.16.5396-5407.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Nucleocytoplasmic Distribution of the Ovalbumin Serpin PI-9
Requires a Nonconventional Nuclear Import Pathway and the Export
Factor Crm1
Catherina H.
Bird,1
Elizabeth J.
Blink,2
Claire E.
Hirst,1
Marguerite S.
Buzza,1
Pauline M.
Steele,1
Jiuru
Sun,1
David A.
Jans,2 and
Phillip I.
Bird1,*
Department of Biochemistry and Molecular
Biology, Monash University, Victoria 3800,1
and Nuclear Signaling Laboratory, John Curtin School of
Medical Research, Australian National University, Canberra ACT
2601,2 Australia
Received 17 May 2001/Accepted 18 May 2001
 |
ABSTRACT |
Proteinase inhibitor 9 (PI-9) is a human serpin present in the
cytoplasm of cytotoxic lymphocytes and epithelial cells. It inhibits
the cytotoxic lymphocyte granule proteinase granzyme B (graB) and is
thought to protect cytotoxic lymphocytes and bystander cells from
graB-mediated apoptosis. Following uptake into cells, graB promotes DNA
degradation, rapidly translocating to the nucleus, where it binds a
nuclear component. PI-9 should therefore be found in cytotoxic
lymphocyte and bystander cell nuclei to ensure complete protection
against graB. Here we demonstrate by microscopy and subcellular
fractionation experiments that PI-9 is present in the nuclei of human
cytotoxic cells, endothelial cells, and epithelial cells. We also show
that the related serpins, PI-6, monocyte neutrophil elastase inhibitor
(MNEI), PI-8, plasminogen activator inhibitor 2 (PAI-2), and the
viral serpin CrmA exhibit similar nucleocytoplasmic distributions.
Because these serpins lack classical nuclear localization signals and
are small enough to diffuse through nuclear pores, we investigated
whether import occurs actively or passively. Large (~70 kDa) chimeric
proteins comprising PI-9, PI-6, PI-8, MNEI, or PAI-2 fused to green
fluorescent protein (GFP) show similar nucleocytoplasmic distributions
to the parent proteins, indicating that nuclear import is active. By
contrast, CrmA-GFP is excluded from nuclei, indicating that CrmA is not
actively imported. In vitro nuclear transport assays show that PI-9
accumulates at a rate above that of passive diffusion, that it requires
cytosolic factors but not ATP, and that it does not bind an
intranuclear component. Furthermore, PI-9 is exported from nuclei via a
leptomycin B-sensitive pathway, implying involvement of the export
factor Crm1p. We conclude that the nucleocytoplasmic distribution of PI-9 and related serpins involves a nonconventional nuclear import pathway and Crm1p.
 |
INTRODUCTION |
Proteolysis mediated by serine
proteinases is crucial to processes such as blood coagulation,
fibrinolysis, complement activation, embryo implantation, extracellular
matrix remodeling, and cell differentiation. Homeostatic regulation of
serine proteinases is mainly achieved through interactions with
inhibitors belonging to the large metazoan, plant, and virus serpin
superfamily (44). Inhibitory serpins have a common
structure and mode of action: each contains a variable
C-terminal-reactive center loop resembling the substrate of its cognate
proteinase. On proteinase binding, the serpin is cleaved between two
residues in the loop designated P1 and
P1', and it undergoes a conformational change
that distorts the proteinase and irreversibly locks the
serpin-proteinase complex (27). The
P1 residue is crucial and largely dictates the
specificity of the serpin-proteinase interaction, while residues
surrounding the cleavage site contribute to the affinity of the
interaction (66).
The best-characterized serpins are involved in the regulation of
extracellular proteolysis in vertebrates (reviewed in references 44 and 54); however, there is an emerging,
more widespread subgroup resembling chicken ovalbumin (ov-serpins)
which includes serpins that function intracellularly and some that
target other proteinase classes, such as caspases and papains
(14, 45, 48, 57). Ov-serpins display complex patterns of
cellular distribution that probably reflect diverse physiological
functions. Most are intracellular, with roles that are as yet unclear,
but some are efficiently secreted to regulate cell-cell and cell-matrix
interactions, and others exist in both intracellular and extracellular
forms (5, 35, 71). Two of the intracellular ov-serpins,
chicken MENT and human bomapin, accumulate efficiently in nuclei via
classical nuclear localization sequences (NLSs) resembling the signal
on the simian virus 40 large tumor antigen (T-ag) (13,
21). MENT is involved in chromatin condensation, but the nuclear
role of bomapin is unknown (21).
Two other intracellular serpins, poxvirus CrmA and human proteinase
inhibitor 9 (PI-9), are involved in the regulation of apoptosis
(reviewed in reference 7). Cytotoxic lymphocytes (CLs)
kill abnormal cells by using either one of two proapoptotic systems
(37, 53). One system involves Fas ligand on the surface of
the CL binding to Fas/Apo1/CD95 (Fas) on the target cell, resulting in
receptor trimerization and recruitment of cytoplasmic adapter molecules
to the receptor complex. The initiator caspase zymogen, procaspase 8, then binds to the complex, is activated, and in turn activates
downstream effector caspases. CrmA efficiently inhibits caspase 8 (70) and potentially protects poxvirus-infected cells
against CL Fas-mediated apoptosis (7).
The second cytotoxic system requires perforin to mediate entry of the
granule serine proteinase granzyme B (graB) into the target cell, which
then activates caspases, cleaves a variety of other proteins, and
rapidly translocates to nuclei inducing DNA fragmentation (reviewed in
reference 59). CLs do not commit fratricide or undergo
autolysis as they sequentially engage and destroy target cells
(19, 33, 38). This implies that their apoptotic machinery
is precisely regulated. We have shown that PI-9 is a very efficient
graB inhibitor produced by CLs (57), endothelial cells,
and epithelial cells (11a). Cells expressing intracellular
PI-9 resist apoptosis induced by graB and perforin but do not resist
Fas-mediated apoptosis, since PI-9 does not efficiently inhibit
caspases (3, 6). We have therefore proposed that the role
of PI-9 is to protect CLs against autolysis directed by ectopic or
misdirected graB and to protect bystander cells from graB released by
activated CLs (6, 8). Importantly, the inability of PI-9
to inhibit caspases allows CLs to be deleted via death
receptor-mediated apoptosis at the conclusion of the immune response
and permits a response to stress-mediated apoptotic signals.
PI-9 is present in the CL cytoplasm outside the granules containing
graB, which is consistent with a role in inactivating mislocalized graB
(57). Since graB introduced into the cytoplasm of a cell
rapidly translocates to the nucleus and binds to an intranuclear
component (31, 52, 61, 62), it is likely that efficient
protection of a CL by PI-9 requires its presence in the nucleus. Here
we show that PI-9 is present in the nuclei of CLs, endothelial cells,
and epithelial cells, that nuclear import occurs in the absence of a
classical NLS, and that related ov-serpins exhibit a similar
nucleocytoplasmic distribution. Although it is small enough to diffuse
into the nucleus, uptake of PI-9 is an active process that depends on
cytosolic factors but not ATP. Export of PI-9 from the nucleus occurs
through a leptomycin B (LMB)-sensitive pathway. We conclude that
nucleocytoplasmic distribution is a common feature of intracellular
ov-serpins consistent with their predicted cytoprotective functions and
appears to involve an unconventional nuclear import pathway as well as
a nuclear export pathway requiring the export receptor Crm1p (exportin).
 |
MATERIALS AND METHODS |
Plasmids.
Plasmids used for expression of various proteins
in COS-1 cells included pCMV/PI-9 (6) and pEUK/PAI-2
(50). A plasmid encoding PI-6 was constructed by
subcloning the cDNA into the EcoRI site of pCMV2
(2). A plasmid encoding PI-8 was made by removing an
internal EcoRI site in the PI-8 cDNA by site-directed mutagenesis and cloning the modified PI-8 cDNA into pSVTf
(34). A monocyte neutrophil elastase inhibitor (MNEI)
expression plasmid was constructed by removing the cDNA from pGEM-T/EI
(41) using SacII (ends removed using T4 DNA
polymerase) and PstI. This was cloned into pSVTf cut with
SmaI and PstI. The plasmid pEGFP/PI-9 encodes a
fusion protein comprising the human codon-enhanced green fluorescent
protein (GFP) fused to the N terminus of PI-9. It was constructed by
isolating a PI-9 cDNA on a 1-kb BamHI fragment from a yeast
two-hybrid bait plasmid, pGTB/PI-9 (A. Calderone and P. Bird,
unpublished data), and ligating it to BglII-digested pEGFP-c2 (Clontech). A similar fusion between neomycin 3'
phosphotransferase (neo) and PI-9 was also constructed. The neo gene
was obtained by PCR amplification using pZeroBlunt (Invitrogen) as a
template, the oligonucleotide primers
5'-GGGCTAGCCGCATGAATTGAACAAGATGGATTGCAC-3' and
5'-CGCTCACCCGGGGAAGAACTCGTCAAGAAGCC-3' (the latter
introduces a SmaI site at the 3' end), and Vent DNA
polymerase (New England Biolabs) for 35 cycles of 95°C for 60 s,
50°C for 60 s, and 72°C for 60 s. The resulting 1-kb
product was cloned into pZeroBlunt (Invitrogen) and then released and
purified as a SmaI-EcoRI fragment. This was
subcloned into pSVTf also digested with SmaI and
EcoRI to generate pSVTf/neo. The plasmid pEGFP/PI-9 was
digested with EagI and treated with T4 DNA polymerase. It
was then cut with SalI, and the resulting 1.4-kb
EagI-SalI fragment was ligated to pSVTf/neo
digested with SmaI and SalI to generate
pSVTf/neoPI-9. A plasmid encoding a GFP-CrmA fusion protein was
constructed by digesting the plasmid pGEM7zf/CrmA (gift of D. Pickup,
Duke University Medical Center, Durham, N.C.) with NcoI
(ends filled in using T4 DNA polymerase) and ApaI. The
resulting fragment was cloned into pEGFP-c2 cut with EcoRI
(ends filled with T4 DNA polymerase) and ApaI. The plasmid
pEGFP/PAI-2 was constructed by removing the plasminogen activator
inhibitor 2 (PAI-2) cDNA from pSHT/PAI-2 (50) by
BamHI (ends filled in using T4 DNA polymerase) and
EcoRI digestion and cloning it into pEGFP-c2 cut with
SacI (ends removed using T4 DNA polymerase) and
EcoRI. The plasmids pEGFP/PI-8 and pEGFP/MNEI were
constructed by removing the appropriate cDNA from pSHT/PI-8 or
pSHT/MNEI (unpublished data) using BamHI and SpeI and cloning into pEGFP-c3 cut with BglII and
XbaI. The plasmid pEGP/PI-6 was constructed by removing the
PI-6 cDNA from the yeast two-hybrid bait vector pGTBK7/PI-6
(unpublished data) using EcoRI and SalI and
cloning it into pEGFP-c2 cut with EcoRI and SalI.
Cells and transfections.
Activated primary CLs were prepared
from human peripheral blood as previously described (6).
YT is a human NK leukemia cell line (68) and was
maintained in RPMI 1640 containing 10% heat-inactivated fetal bovine
serum, 50 U of penicillin/ml, 50 µg of streptomycin/ml, 2 mM
glutamine, 0.1 mM
-mercaptoethanol, and 1 mM sodium pyruvate. The
placental choriocarcinoma cell line BeWo was obtained from the American
Type Culture Collection and was maintained in Ham's F12 containing
10% heat-inactivated fetal bovine serum, 50 U of penicillin/ml, 50 µg of streptomycin/ml, 2 mM glutamine. Human umbilical vein
endothelial cells (HUVEC) were isolated and maintained as described
(58). COS-1 cells were maintained in Dulbecco's modified
Eagle's medium (DMEM) containing 10% fetal bovine serum, antibiotics,
and 2 mM glutamine. Cells of the rat hepatoma tissue culture line (HTC;
a derivative of Morris hepatoma 7288C) used for the in vitro transport
studies were cultured in DMEM supplemented with 10% fetal bovine serum as described previously (26, 29, 30). COS-1 cells were
transiently transfected by the dextran-chloroquine method
(12).
Antibodies.
Rabbit antibodies to recombinant PI-9 and
recombinant PI-6 have been described earlier (50, 57). A
rabbit polyclonal antiserum to PI-8 was raised in a similar fashion and
affinity purified on immobilized recombinant PI-8. Rabbit antibodies
raised to native MNEI, CrmA, and lactate dehydrogenase (LDH) were
provided by E. Remold O'Donnell (Harvard University, Boston, Mass.),
D. Pickup (Duke University Medical Center), and J. Wilson (Michigan
State University, East Lansing, Mich.), respectively. A rat monoclonal antibody against human Apaf-1 (23) was a gift of D. Huang
(Walter and Eliza Hall Institute, Melbourne, Australia). Mouse
monoclonal antibodies to cytochrome c and PAI-2 were
purchased from Research Diagnostics Inc. (clone 7H8.2C12; Flanders,
N.J.) and American Diagnostica Inc. (Greenwich, Conn.), respectively.
Anti-GFP monoclonal antibody was purchased from Boehringer Mannheim.
The nuclear protein B23 was detected using a mouse monoclonal antibody
(40). Rabbit pan-cytokeratin antibodies were purchased
from DAKO.
Cell fractionation.
Methods for the digitonin-based
fractionation of YT, BeWo, and transfected COS-1 cells were based on
previously published methods (23, 63, 65). A range of
digitonin concentrations was tested in each experiment, and the results
shown are those from cells treated with the lowest concentration that
efficiently extracted the cytosolic marker protein (either LDH or
Apaf-1) such that little or none was apparent in the subsequent nuclear fraction. Monolayers were removed from dishes by trypsinization and
washed twice with ice-cold medium containing fetal calf serum and then
washed once with ice-cold phosphate-buffered saline (PBS). Cells were
counted and resuspended at 106/ml in HMKE buffer
(20 mM HEPES [pH 7.2], 10 mM KCl, 5 mM MgCl2, 1 mM EDTA, 250 mM sucrose). One-milliliter aliquots were pelleted at
approximately 200 × g and resuspended in HMKE buffer
containing protease inhibitors (1 mM phenylmethylsulfonyl fluoride, 1 µg of aprotinin/ml, 1 µg of pepstatin/ml, 1 µg of leupeptin/ml)
and 50 to 200 µg of digitonin/ml (Sigma; 50-mg/ml stock in
dimethyl sulfoxide). Cells were left on ice for 10 min and then
centrifuged at 500 × g to separate cytosol from
membranes, organelles, and cytoskeleton. The supernatant (cytosol
fraction C) was carefully removed, and the pellet was washed in HMKE
buffer. To extract proteins from membranes and organelles, the pellet
was solubilized in extraction buffer containing 0.1 M Tris HCl (pH 9),
0.1 M NaCl, 5 mM KCl, 1 mM CaCl2, 0.5 mM
MgCl2, 0.5% Nonidet P-40, and protease inhibitors for 20 min on ice. Samples were transferred to a 1.5-ml microcentrifuge tube and centrifuged at 15,000 × g, the supernatant was carefully removed (fraction N), and a
solution containing 20 mM Tris HCl (pH 6.8) and 2% sodium dodecyl
sulfate (SDS) was added to the pellet to solubilize cytoskeletal
proteins. The resulting lysate was collected and passed through a 26G
needle until no longer viscous (fraction R).
The protein content of fraction C was determined, and typically 10 µg
of protein was used for immunoblotting. The detergent in fractions N
and R precluded direct protein estimation. To analyze and compare
protein complement and distribution in the fractions, all were made up
to the same final volume so that a sample taken from one fraction and
compared to an equal volume from another represents the same number of
starting cells. In each experiment, equal volumes of fractions C, N,
and R were reduced and subjected to electrophoresis on SDS-10%
polyacrylamide gels. Fractionation of COS cells producing CrmA
was performed according to the methods of Schikendanz et al.
(49).
Rabbit antisera (PI-6, PI-9, and MNEI) were used at 1:2,000 to 1:5,000
dilutions for immunoblotting, and the B23 monoclonal antibody was used
at a dilution of 1:4,000. The CrmA and PI-8 antisera were used at
dilutions of 1:100. The Apaf-1, cytochrome c, PAI-2, LDH,
and GFP antibodies were used at dilutions of 1:1,000. Immunoblots were
developed with an enhanced chemiluminescence detection kit (DuPont).
Indirect immunofluorescence microscopy and in situ cell
extractions.
Cell monolayers grown on 12-well microscope slides
were washed in PBS containing 0.1 mM CaCl2 and
1.0 mM MgCl2 (PBS+), fixed in 3.7% formaldehyde
in PBS+ for 20 min, quenched with 20 mM ammonium chloride, and
permeabilized by incubation in 0.5% Triton X-100 in PBS+ for 5 min.
Alternatively, monolayers were fixed and permeabilized in 50%
acetone-50% methanol for 2 min at room temperature. Glass slides used
for nonadherent cells were first treated with poly-L-lysine (0.1 mg/ml) for 15 min at room temperature. Antigens were detected by
incubation of the cells for 30 min with the appropriate dilution of
primary antibody (typically 1:1,000 for PI-6 and PI-9 antisera, 1:50
for Apaf-1 antibodies, and 1:200 for all others). After being washed
with PBS+ the cells were incubated with 1:200 dilutions of fluorescein
isothiocyanate (FITC)- or rhodamine isothiocyanate-conjugated secondary
antibodies. After 30 min cells were washed in PBS+ and, in some
experiments, were stained with propidium iodide (1-µg/ml concentration in PBS) for 5 min at room temperature. Cells were washed,
mounted in phenlyenediamine-buffered glycerol, and examined using
either epifluorescence microscopy or confocal laser scanning microscopy
(CLSM). In some indicated instances CLSM using 2-photon excitation was employed.
For in situ extractions, 104 BeWo cells per well
were grown on 12-well microscope slides. Untreated cells were fixed and
permeabilized as described above. Cells were stained with rabbit
anti-PI-9 (1:1,000 dilution), rabbit anti-cytokeratin (1:200), and
anti-Apaf-1 (1:50) followed by a 1:200 dilution of the appropriate
secondary antibody conjugated to FITC. To remove proteins from the
cytoplasm, cells were placed on ice, washed twice with ice-cold HMKE
buffer, and then exposed to digitonin (25, 50, or 75 µg/ml) in 20 µl of HMKE buffer containing protease inhibitors for 10 min. At this
point cells were either fixed for staining as above (digitonin treated) or washed with HMKE buffer and then incubated in 20 µl of extraction buffer for 10 min to remove detergent-soluble and salt-extractable (including most nuclear) proteins. The remaining monolayers were washed
very gently and then fixed with formaldehyde and stained as above to
visualize detergent-insoluble proteins.
Nuclear transport.
Analysis of nuclear import kinetics at
the single-cell level in vitro using mechanically perforated HTC cells
in conjunction with CLSM (MRC-600; Bio-Rad) was performed as described
previously (10, 16, 29). NLS-dependent nuclear protein
import can be reconstituted in this system through the exogenous
addition of cytosolic extract (untreated reticulocyte lysate
[Promega]), an ATP regenerating system (0.125 mg of creatine
kinase/ml, 30 mM creatine-phosphate, 2 mM ATP), and transport
substrate. In some experiments 0.025%
3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonate (CHAPS)
was used to permeabilize the nuclear envelope; under these conditions
nuclear accumulation can only occur through binding to intranuclear
components such as lamins or chromatin (16, 17). Image
analysis of CLSM files was performed using the MacIntosh NIH Image 1.60 public domain software. Each point shown in Results (Table
1 and Fig. 5) represents the average of 6 to 10 separate measurements (the standard error of the mean [SEM] was
<10.2% of the value of the mean) for each of nuclear (Fn) and
cytoplasmic (Fc) fluorescence, respectively, with autofluorescence
subtracted. Data were fitted for the function Fn/c(t) = Fn/cmax × (1
e
kt), where Fn/c is the ratio
of nuclear to cytoplasmic fluorescence intensity, t is time
in minutes, Fn/cmax is the maximal level of
nuclear accumulation, and k is the first-order rate constant (10, 16, 29). Recombinant PI-9 was produced in a yeast
expression system and purified as described previously
(57) and was conjugated to FITC using standard procedures
(22). The T-ag-CcN-
-Gal fusion protein used as
a control for nuclear import studies contains T-ag amino acids 111 to
135, including the NLS, fused N terminal to
-galactosidase amino
acids 9 to 1,023 (29, 46). It was expressed in
Escherichia coli, purified by affinity chromatography, and
labeled with 5-iodoacetamidofluorescein as described previously (29, 46).
Estimation of the proportion of nuclear PI-9.
Estimation of
the nuclear and cytoplasmic volume for BeWo cells, YT cells, and
HUVECs was performed using conventional as well as 2-photon CLSM
(Bio-Rad) and standard cell measurement procedures. The percent nuclear
PI-9 was calculated by multiplying the percent nuclear volume (>11
separate estimations) by the Fn/c for each cell type.
Treatment of cells with LMB.
COS-1 cells were transfected
with pCMV/PI-9 or RevMAPKK-GFP (24). Cells grown on
12-well microscope slides were exposed to 4 ng of LMB/ml in complete
medium for 0, 3, and 6 h and then fixed with formaldehyde and
permeabilized as described above. RevMAPKK/GFP in transfected cells was
followed by GFP fluorescence, whereas pCMV/PI-9-transfected cells were
stained with rabbit anti-PI-9 diluted 1:500 and then with
FITC-conjugated anti-rabbit immunoglobulins. Samples were mounted in
Permafluor (Immunotech, Marseille, France). Quantitative
analysis for nucleocytoplasmic distribution was performed as for the
nuclear transport studies, where nontransfected cells were used to
quantify background fluorescence due to autofluorescence or nonspecific
staining by antibodies. Measurements of nucleolar fluorescence of cells
producing RevMAPKK/GFP were carried out in a similar fashion.
 |
RESULTS |
PI-9 is present in CL, endothelial cell, and epithelial cell
nuclei.
We have proposed that intracellular PI-9 protects CLs and
bystander cells against mislocalized graB resulting from either granule
leakage or misdirection during the immune response (6). Since free graB in the cell rapidly translocates from the cytoplasm to
the nucleus (31, 52, 61, 62), the model predicts that PI-9
should also be present in nuclei to deal with any graB that evades the
cytoplasmic pool of PI-9. To test this prediction we used indirect
immunofluorescence and CLSM to examine primary human CLs prepared from
peripheral blood, HUVECs, and the human cell lines YT (NK leukemia) and
BeWo (choriocarcinoma). We have previously demonstrated that all of
these cell types produce PI-9.
Shown in Fig. 1A is a series of confocal
sections through a cluster of primary CLs that have been fixed,
permeabilized, and stained for PI-9 (upper panel). In these cells the
nucleus occupies most of the interior (shown by propidium iodide
staining in the lower panel), and the cytoplasm is evident as a thin
halo surrounding it. It is clear from these images that PI-9 is present
in the cytoplasm and nucleus, though at lower concentration in the
nucleus. Similar experiments on YT cells confirmed these observations
(Fig. 1B and C). Again PI-9 was evident in both cytoplasm and nucleus, with less material in the nucleus.

View larger version (49K):
[in this window]
[in a new window]
|
FIG. 1.
Nucleocytoplasmic distribution of PI-9. (A) Human
primary CLs. Interleukin-2-activated CLs were prepared from peripheral
blood. Cells on glass slides were fixed and permeabilized with
acetone-methanol and were incubated with rabbit antiserum against PI-9
and then incubated with FITC-conjugated anti-rabbit immunoglobulin and
propidium iodide (p.i.). A series of CLSM sections through a cluster of
cells shows PI-9 in both the nucleus and cytoplasm. (B) YT cells. Cells
were fixed and stained as above. Shown is a series of CLSM sections of
a single YT cell demonstrating PI-9 in the cytoplasm and nucleus. (C)
Relative expression level and proportion of PI-9 in the nuclei of BeWo
cells, YT cells, and HUVECs. Estimations of the nuclear and cytoplasmic
volumes were performed using conventional and 2-photon CLSM and
standard cell measurement procedures. The percent nuclear PI-9 was
calculated by multiplying the percent nuclear volume by the ratio of
nuclear to cytoplasmic fluorescence intensity (Fn/c). For comparison of
PI-9 levels, 106 cells were lysed directly in SDS sample
buffer, separated by SDS-polyacrylamide gel electrophoresis, and
immunoblotted using PI-9 antibodies. Ten times more HUVEC than
BeWo or YT lysate was run on the gel. (D) Concentration of
PI-9 in the cytoplasm and nuclei of YT cells, BeWo cells, and HUVECs as
measured by relative fluorescence intensity under CLSM. Results shown
for the Fn/c ratio represent the mean ± SEM, with
n being the number of cells analyzed.
|
|
As shown in Fig. 1C, we also observed PI-9 in the cytoplasm and nucleus
of primary endothelial cells (HUVECs) and BeWo cells (which have
epithelial characteristics of placental cytotrophoblasts). PI-9 levels
in BeWo cells were comparable to those in YT cells, but levels in
HUVECs were 10- to 100-fold lower (Fig. 1C, bottom left panel).
Interestingly, the amount of PI-9 in the nucleus differed in the
various cell types but did not seem to be related to the overall
expression level of PI-9. To investigate this further we used CLSM and
image analysis to measure the proportion of PI-9 in the nuclei of YT
cells, HUVECs, and BeWo cells (Fig. 1C). This indicated that YT cells
have the least PI-9 in the nucleus (26.5%) and that BeWo cells have
the most (40.9%). Since the size of the nucleus varies from cell type
to cell type, the concentration of PI-9 in the nucleus compared to the
concentration in the cytoplasm may also vary. To investigate this we
used image analysis to derive a value for the nuclear-to-cytoplasmic
ratio (Fn/c) of PI-9 in the three cell types. As shown in Fig. 1D, YT
cells have about twice the concentration of PI-9 in the cytoplasm as
the nucleus, whereas HUVECs and BeWo cells have an equal concentration
of PI-9 in the cytoplasm and nucleus.
To confirm that PI-9 is present in the nuclei of these cells we carried
out two digitonin-based fractionation procedures. One involved
sequential extraction of protein from cells in situ with changes in
protein content followed at the single-cell level using indirect
immunofluorescence microscopy, and the other entailed fractionation of
larger numbers of cells with analysis of the fractions by
immunoblotting. Digitonin is extensively used in in vitro nuclear
import studies to separate nuclei with intact envelopes and functional
pore complexes from cytosolic components because it selectively
permeabilizes the plasma membrane, leaving the nuclear membrane intact
(23, 63, 65). Following digitonin treatment and washing to
remove cytosolic protein, nuclei can be lysed in a high-salt buffer
containing detergent to release nuclear proteins. Any remaining
insoluble material contains mostly cytoskeletal and some nuclear or
nucleolar protein that can be solubilized in SDS. In both
procedures we expected to extract cytosolic, nuclear, and cytoskeletal
protein sequentially. To verify this we followed the release of the
cytosolic protein Apaf-1 (23), the nuclear or nucleolar
protein B23 (40), and cytoskeletal cytokeratins.
As shown in Fig 2A, in situ extractions
demonstrated PI-9 in the nuclei of BeWo cells. Untreated cells showed
PI-9 in the cytoplasm and nucleus (upper left panel), Apaf-1 in the
cytoplasm (upper center panel), and cytokeratin throughout the cell
(upper right panel). Treatment of cells with digitonin completely
removed Apaf-1 from the cytoplasm (middle center panel) but did not
fully release PI-9 from cells, as the protein is clearly still evident in nuclei (middle left panel). Cytokeratin was not removed by digitonin
treatment (right middle panel). Subsequent extraction with high salt
and detergent completely removed PI-9 from nuclei (lower left panel)
but did not remove cytokeratin from the cells (lower right panel),
indicating that PI-9 is not associated with the cytoskeleton. In situ
extraction experiments on HUVECs and YT cells yielded similar results
(data not shown).

View larger version (63K):
[in this window]
[in a new window]
|
FIG. 2.
In situ extraction and subcellular fractionation of PI-9
expressing cells. (A) BeWo cells growing on microscope slides were
sequentially extracted with digitonin-containing and high
salt-detergent-containing buffers. After each treatment, cells
were fixed and permeabilized with acetone-methanol and incubated with
antibodies against PI-9, Apaf-1, or cytokeratins. After being stained
with FITC-conjugated anti-rabbit immunoglobulins, the cells were
examined by phase-contrast (inset panels) and fluorescence microscopy.
(B) YT cells, BeWo cells, and HUVECs were harvested and sequentially
treated with digitonin, high salt-detergent, and SDS to generate
cytosolic (C), nuclear (N), and remnant (R) fractions. Equal amounts of
each fraction were separated by SDS-10% polyacrylamide gel
electrophoresis and analyzed by immunoblotting with PI-9, Apaf-1, or
B23 antibodies. The percentage of PI-9 in the nuclear fraction was
estimated by densitometry. The PI-9-graB complex is indicated with an
arrow.
|
|
Immunoblotting analysis of digitonin-treated HUVECs, YT cells, and BeWo
cells separated into cytoplasmic (C), nuclear (N), and remnant (R)
fractions confirmed the results of the single-cell extraction procedure
(Fig. 2B). PI-9 was evident in both the cytoplasmic and nuclear
fractions of all the cell types and was not associated with
cytoskeletal material. Densitometry was used to estimate the amount of
nuclear PI-9 in these cells (Fig. 2B), and the resulting values were in
very good agreement with the results of the confocal analysis (Fig.
1C).
The higher-molecular-weight species seen in both the cytosolic and
nuclear fractions of YT cells represents PI-9 complexed with graB.
Complex formation is a postlysis phenomenon, as graB is released from
granules by detergents and rapidly equilibrates between the cytosol and
nucleus via an unknown mechanism (61). We have shown
previously that if cells are broken mechanically and intact granules
are separated from the soluble components, little or no complex is
detected in the cytosol (57). Furthermore, if whole cells
are lysed rapidly in SDS sample buffer, no complexes are observed (data
not shown).
Taken together, the above results clearly show that PI-9 has a
nucleocytoplasmic distribution in accordance with our cytoprotective model and that the proportion of PI-9 in the nucleus is not related to
the expression level. To see if the nuclear localization of PI-9
requires a pathway or factors peculiar to HUVECs, YT cells, or BeWo
cells, we also examined a number of other human cell lines of lymphoid
or epithelial origin (SKW6, MCF7, HeLa) that are normally PI-9 negative
but have been stably transfected with PI-9 cDNAs. In every case PI-9
was present in both the cell cytoplasm and nucleus (data not shown). We
also expressed PI-9 in transiently transfected COS-1 cells (Fig.
3A). Fractionation experiments and epifluorescence microscopy of cells stained with rabbit anti-PI-9 antibodies showed PI-9 in both the cytoplasm and nucleus in these cells
(Fig. 3A), and the concentration of nuclear PI-9 in transfected COS
cells was similar to that of YT cells (Fn/c, ~0.5; see Fig. 6B).
Thus, nuclear localization of PI-9 is unlikely to require cell
type-specific machinery.

View larger version (66K):
[in this window]
[in a new window]
|
FIG. 3.
Nucleocytoplasmic distribution of PI-9-related
ov-serpins. COS-1 cells transiently transfected with appropriate
expression vectors were grown either on glass slides for examination by
indirect immunofluorescence or in dishes for cytosolic and nuclear
fractionation experiments. Cells expressing either PI-9 (A), PI-6 (B),
PI-8 (C), MNEI (D), PAI-2 (E), or CrmA (F) were fixed and stained with
appropriate primary antibodies and then with FITC-conjugated secondary
antibodies. In each case the images clearly show the serpin in the
cytoplasm and nucleus. The distribution of protein within cytosolic
(C), nuclear (N), or remnant (R) fractions in each transfected line was
determined by immunoblotting. Also shown are the LDH and B23 controls
for each experiment. CrmA-transfected cells were fractionated according
to previously published methods (49), and cytochrome
c (cyt) was used to monitor release of cytoplasmic
protein.
|
|
Related ov-serpins also exhibit a nucleocytoplasmic
distribution.
PI-9 belongs to the ov-serpin family that comprises
intracellular proteins very similar in structure and size. Two
ov-serpins (MENT and bomapin) possess conventional nuclear import
signals located in a region of the molecule known as the interhelical loop (13, 21). PI-9 lacks this loop and has no
identifiable NLS, implying that its uptake into the nucleus occurs via
a different mechanism. To determine if this type of nuclear
accumulation is unique to PI-9, we transiently transfected COS-1 cells
with expression vectors encoding other ov-serpins lacking the
interhelical loop and an identifiable NLS (PI-6, PI-8, MNEI) with an
ov-serpin containing the loop but no obvious import signal (PAI-2) and
with the viral intracellular serpin, CrmA. Cells were either
fractionated for analysis by immunoblotting or plated on glass slides
and prepared for examination by indirect immunofluorescence microscopy
(Fig. 3). In every case, expression in the nucleus was detected by both methods, although the cytoplasmic-to-nuclear ratio varied from protein
to protein. With the exception of PAI-2 (Fig. 3E), there was generally
good correlation between the proportion of protein observed in the
nuclei by microscopy and the amount evident by subcellular
fractionation. For PAI-2 there appeared to be more material in the
nucleus by microscopy than was indicated by analysis of fractions. The
reason for the discrepancy is unknown but may reflect postlysis
modification in the nuclear fractions of the epitope for the PAI-2
monoclonal antibody so that the protein is no longer recognized
efficiently. This explanation is supported by the experiments on the
GFP-PAI-2 fusion protein (Fig. 4D) in which a different monoclonal antibody was used (anti-GFP) and no such
discrepancy between the two methods was evident.

View larger version (59K):
[in this window]
[in a new window]
|
FIG. 4.
PI-9 is imported into the nucleus through a facilitated
mechanism. COS-1 cells were transfected with expression vectors
encoding GFP-PI-9 (A), neo-PI-9 (B), GFP-PAI-2 (C), or GFP-CrmA (D),
examined by indirect immunofluorescence microscopy, or fractionated
into cytosolic and nuclear components. Cells were fixed and
permeabilized using acetone-methanol and then incubated with primary
antibodies (GFP-CrmA and GFP-PAI-2 were monitored using a
monoclonal antibody against GFP) and the appropriate FITC-conjugated
secondary antibodies. The distribution of protein within cytosolic (C),
nuclear (N), or remnant (R) fractions in each transfected line was
determined by immunoblotting with the same primary antibodies. Also
shown are the LDH and B23 controls for each experiment.
|
|
Finally, examination of primary human monocytes and mesothelial cells,
which endogenously produce PAI-2, PI-6, and MNEI (51 and
unpublished results), showed nucleocytoplasmic distributions of the
three proteins (data not shown). Taken together, these results indicate
that nucleocytoplasmic localization is a common feature of ov-serpins.
Nuclear accumulation of PI-9 is an active process.
Proteins up
to 40 to 60 kDa can pass freely through the nuclear pore complex.
However, even very small proteins with specific nuclear functions carry
NLSs, ensuring efficient nuclear targeting. Examination of the amino
acid sequence of PI-9 and related serpins failed to reveal known
classical, bipartite, or hnRNP A1 M9-like import signals
(39). The lack of an identifiable NLS together with its
relatively small size (42 kDa) suggested that PI-9 enters the nucleus
by passive diffusion. To test this we generated a chimeric protein
(GFP-PI-9) consisting of GFP (27 kDa) fused to the N terminus of PI-9.
If PI-9 diffuses into the nucleus and does not require a dedicated NLS,
the 69-kDa fusion protein should be excluded from the nucleus because
it is too large to move through the pores.
By microscopy the fusion protein produced in transfected COS-1 cells
was evident in both cytoplasm and nuclei (Fig. 4A). Fractionation experiments showed the 69-kDa fusion protein in the cytoplasm and
nucleus, and densitometry indicated that the same proportion of
GFP-PI-9 as PI-9 is found in nuclear fractions (approximately 20 to
30%). Pulse-chase experiments of metabolically labeled cells over
5 h showed that the fusion protein is stable and that no degradation into smaller (potentially diffusible) fragments occurred (data not shown).
To rule out the generation of a cryptic NLS during the construction of
GFP-PI-9, we made a similar fusion (neo-PI-9) between the 28-kDa
aminoglycoside 3'-phosphotransferase (neo) protein and PI-9. Like GFP,
neo is small enough to passively enter the nucleus, but the chimeric
protein should be too large to do so. Fractionation experiments and
microscopy revealed that neo-PI-9 also enters the nucleus (Fig. 4B).
Taken together these results suggest that although PI-9 is under the
nominal nuclear pore cutoff, it enters the nucleus in a facilitated process.
To determine whether facilitated nuclear import is unique to PI-9, we
also constructed similar fusion proteins consisting of GFP linked to
PAI-2, PI-6, MNEI, PI-8, or CrmA. As judged by microscopy and
fractionation of transfected COS cells, the GFP-PAI-2 fusion protein
accumulated in the nucleus as efficiently as PAI-2 alone (Fig. 4C). By
contrast, the GFP-CrmA fusion protein was essentially excluded from the
nucleus (Fig. 4D), indicating that CrmA is not actively imported and
that CrmA observed in the nucleus results from diffusion only (see Fig.
3F). Fusions between GFP and PI-6, MNEI, or PI-8 showed distributions
similar to those of the parent proteins (data not shown). These results
demonstrate that PI-9 and related ov-serpins can be imported into
nuclei via a facilitated mechanism that does not depend on a classical NLS.
Nuclear uptake of PI-9 requires cytosolic factors but not ATP.
Nuclear accumulation of PI-9 was also examined in vitro. As shown in
Fig. 5, the nuclear import properties of
FITC-labeled recombinant PI-9 were compared to those of control
molecules at the single-cell level in mechanically perforated HTC cells
(29). Addition of exogenous cytosol and an ATP-generating
system to the HTC cells is sufficient to reconstitute nuclear
transport, as shown by the uptake of the well-characterized chimeric
protein (T-ag-CcN-
-Gal) which comprises a conventional NLS derived
from T-Ag fused to the N terminus of E. coli
-galactosidase (46). This protein accumulated in the
nucleus to levels over fivefold greater than those in the cytoplasm,
with half-maximal accumulation achieved within 12 min (Table 1). By
contrast, 70-kDa dextran was excluded from the nucleus
(Fn/cmax of about 0.2), while 20-kDa dextran
equilibrated between nuclear and cytoplasmic compartments but did not
accumulate in the nucleus (Fn/cmax of about 1).
In this system, nuclear accumulation of PI-9 in HTC cell nuclei was observed, occurring to a maximum of 2.5 times that of the cytoplasmic levels, with transport half maximal within 2 min (Table 1 and Fig. 5A).

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 5.
Nuclear import kinetics of PI-9 in vitro. Uptake of
FITC-conjugated PI-9 and dextran was examined in mechanically
perforated HTC cells at room temperature in the presence (A) or absence
(B) of exogenous cytosol and/or an ATP regenerating system as
indicated. (C) CLSM images of nuclei 20 min after the addition of the
indicated components. Fn/c is the ratio of nuclear to cytoplasmic
fluorescence. Table 1 shows pooled data.
|
|
Conventional signal-mediated nuclear protein import in vitro is
dependent on energy in the form of ATP and exogenous cytosol (20), the latter containing the NLS-recognizing importin
heterodimer, the monomeric guanine nucleotide-binding protein Ran, and
other interacting proteins essential for nuclear accumulation
(20). The conventional NLS-containing fusion protein
T-ag-CcN-
-Gal requires both ATP and cytosol for nuclear
accumulation (see Table 1 and reference 17). By contrast,
nuclear import of PI-9 required cytosol but not ATP (Fig. 5B and Table
1).
The detergent CHAPS can be used to perforate the nuclear envelope to
enable molecules to diffuse freely between cytoplasm and nucleoplasm
(16, 17). For example, 70-kDa dextran is no longer
excluded from nuclei after CHAPS treatment (Table 1). In the presence
of CHAPS, nuclear accumulation can occur only through binding to
nuclear components (16, 17). As demonstrated by
T-ag-CcN-
-gal (Table 1), most proteins containing classical nuclear import signals do not exhibit nuclear accumulation in the
presence of CHAPS; instead they equilibrate between the nuclear and
cytoplasmic compartments. Likewise, in the presence of CHAPS PI-9 did
not accumulate in the nucleus in either the absence or presence of
cytosol (Table 1) and is thus clearly unable to bind to nuclear
components and/or accumulate in the nucleus under these conditions.
This contrasts with graB, which accumulates in nuclei in the presence
of CHAPS by binding a nuclear component (28). In summary,
PI-9 appears to accumulate in the nucleus through a novel nuclear
import pathway which requires cytosolic factors, does not require ATP,
and does not involve intranuclear binding.
Export of PI-9 from the nucleus occurs via a LMB-sensitive
pathway.
PI-9 is detectable in both the nucleus and the cytoplasm
of the cell. Since PI-9 is able to localize strongly in the nucleus via
a facilitated mechanism, it is likely that active export of PI-9 from
the nucleus to the cytoplasm occurs in order to maintain the correct
nucleocytoplasmic distribution. Most proteins exported from the nucleus
travel on a pathway that can be blocked by the compound LMB
(20). We therefore tested the ability of LMB to inhibit
the export of PI-9, as indicated by increased nuclear accumulation of
PI-9 in LMB-treated cells. As a control for LMB activity we obtained a
plasmid encoding a mutant form of nucleolar human immunodeficiency
virus (HIV) Rev linked to GFP (RevMAPKK/GFP) (24). This
fusion protein also carries a strong, heterologous nuclear export
signal (NES) from mitogen-activated protein kinase kinase. Under
normal conditions, in the absence of LMB the vast majority of this
protein is present in the cytoplasm, since the rate of nuclear export
directed by this NES is far greater than that of nuclear import
(24). However, in the presence of LMB nuclear export is
prevented and there is a dramatic shift from predominantly cytoplasmic
to predominantly nuclear compartmentalization of RevMAPKK/GFP, with
most accumulation in the nucleoli, as expected for Rev
(43).
COS-1 cells expressing PI-9 or RevMAPKK/GFP were exposed to LMB for 0, 3, or 6 h and then were examined by indirect immunofluorescence using CLSM to measure the ratio of fluorescence intensities in the
cytosol and nucleus at the single-cell level (Fig.
6). As expected, RevMAPKK/GFP rapidly
accumulated in the nucleolus, peaking at 3 h with a concentration
40- to 50-fold higher in the nucleolus than in the cytoplasm. Some
RevMAPKK/GFP accumulated in the nucleus outside the nucleolus, and this
concentration was fivefold higher than that in the cytoplasm. Nuclear
accumulation of PI-9 was also observed, peaking at 3 h with two to
three times the concentration in the nucleus than that in the
cytoplasm. This represented a significant shift from untreated cells,
which show about twice the concentration of PI-9 in the cytoplasm as
that in the nucleus. These results clearly show that PI-9 is actively
exported from the nucleus through a mechanism dependent on Crm1p
(exportin).

View larger version (51K):
[in this window]
[in a new window]
|
FIG. 6.
Nuclear export of PI-9 is blocked by LMB. COS-1 cells
transfected with the expression vectors encoding PI-9 or RevMAPKK/GFP
were exposed to 4 ng of LMB/ml for the indicated times. Cells were
prepared for visualization (A) and quantitation (B) of
nuclear/cytoplasmic ratios (Fn/c) or nucleolar/cytoplasmic ratios
(Fnu/c by CLSM as described in Materials and Methods). Results are the
mean ± SEM, with n being the number of cells
analyzed.
|
|
 |
DISCUSSION |
The ov-serpins are an emerging subgroup of the serpin
superfamily distinguished by their largely intracellular localization. Indeed, most of the new serpins recently identified through
whole-genome analysis of Caenorhabditis elegans and
Drosophila melanogaster have the characteristics of
intracellular proteins (67 and A. Lesk, P. Bird, and J. Whisstock, unpublished results). Although 1 of the 12 human ov-serpins
(bomapin) is imported into the nucleus via a classical NLS
(13), we show here for the first time that PI-9 and at
least four related human ov-serpins (PAI-2, MNEI, PI-6, and PI-8) enter
nuclei without possessing obvious classical nuclear import signals. On
the basis of the behavior of GFP fusion proteins, it is clear that
import of these serpins depends almost entirely on a facilitated
(active) pathway. This contrasts with the viral intracellular serpin
CrmA, which has functional similarities to PI-9 but apparently enters
the nucleus entirely by diffusion. On the basis of our results, it is
reasonable to suggest that other ov-serpins
and perhaps unrelated
intracellular serpins
will exhibit similar subcellular localization.
A nucleocytoplasmic distribution pattern is consistent with the
proposed cytoprotective roles of several of these serpins. For example,
it is thought that PI-9 protects cytotoxic and bystander cells against
misdirected graB, which is known to translocate efficiently from the
cytoplasm to the nucleus of cytotoxic and target cells and to degrade
cytoplasmic and nuclear substrates (60). Obviously, the
presence of PI-9 in both the cytoplasm and nucleus of a cell would
provide efficient protection against graB-mediated damage. Likewise,
PI-6 and MNEI inhibit the monocyte and granulocyte granule proteinases,
elastase, cathepsin G, and proteinase 3, and may also protect cells
against protease-directed autolysis (51, 56). These
proteinases are all small enough to enter nuclei by diffusion, so that
if introduced into the host cell cytoplasm they have the potential to
threaten viability in a manner similar to that of misdirected graB in
cytotoxic cells. Indeed, cathepsin G can activate caspase 7 via
cleavage at a noncanonical site (69) and cleaves the
nuclear protein brm (5a), suggesting it is
proapoptotic if released into the interior of the cell. The
presence of PI-6 and MNEI in the nucleus as well as the cytoplasm therefore offers the cell an additional level of protection against misdirected granule proteinases. A similar protective role can be
invoked for two other ov-serpins, SCCA-1 and SCCA-2, that were not
investigated in this study. These proteins interact with lysosomal and
mast cell proteinases, respectively (47, 48). Given that loss of lysosomal membrane integrity and the release of contents into
the cytoplasm are known to occur under stress (11) and that lysosomal proteinases are also small enough to diffuse into the
nucleus, it is possible that the SCCAs will also exhibit a nucleocytoplasmic distribution.
The role of PAI-2 in cells is probably different from that of other
ov-serpins, although still cytoprotective in scope. PAI-2 protects
cells against tumor necrosis factor alpha-mediated apoptosis (15) and virus infection (4). Protection
against virus infection occurs through PAI-2-mediated induction of
autocrine alpha and beta interferon, and it has been suggested that
PAI-2 acts on a transcription factor pathway (4). Although
the intracellular targets of PAI-2 are unknown, the presence of PAI-2
in the nucleus is certainly consistent with a direct or indirect impact
on the transcription of cytoprotective factors.
An interesting question not addressed in our study is whether the
nucleocytoplasmic distribution of PI-9 and other intracellular ov-serpins is regulated, in that levels of nuclear import or export alter in response to specific signals. Clearly different cell types
show different proportions of nuclear PI-9 (compare HUVECs, YT cells,
and BeWo cells), and this is not related to the expression level of
PI-9, ruling out saturation of the nuclear import machinery. While
different cells may possess different levels of key mediators of PI-9
import or export, an alternative possibility is that the nucleocytoplasmic distribution of PI-9 is actively regulated. There are
several specific mechanisms by which nuclear transport can be
regulated, perhaps the best known being cytoplasmic retention, in which
a nuclear-targeted protein is held in the cytoplasm by binding either
to an anchored structure or to a partner that sequesters its NLS
(25). Signal-mediated phosphorylation or proteolysis then
releases the protein by disrupting binding or revealing its NLS,
allowing import to occur. It remains to be seen if the
nucleocytoplasmic distribution of PI-9 and related ov-serpins alters in
response to cell activation, differentiation, stress, or other stimuli and whether they have intracellular binding partners.
The structure of the nuclear pore and the main players in the import
machinery are reasonably well understood (for reviews, see references
1 and 20). Import of proteins carrying a
classical NLS involves the formation of a complex between the cargo,
importin-
(adapter), and importin-
. In a process requiring
energy, a G protein (Ran), Ran-binding proteins, guanine nucleotide
exchange factors, and GTPase activators the complex docks at the
nuclear pore, is translocated through it, and then dissociates within the nucleoplasm. Several lines of evidence suggest that alternative import routes and components are used by proteins lacking classical import signals. For example, importin-
family members can mediate the import of ribosomal proteins independently of importin-
, and
other Ran-binding proteins have also been implicated in adapter-free transport. In this study we have shown that PI-9 accumulates in the
nucleus via an atypical import pathway that requires cytosolic factors
but not ATP, which may also hold true for other ov-serpins. Although it
lacks an apparent classical NLS, PI-9 is imported via a facilitated
process, as indicated by its ability to mediate uptake of large fusion
proteins. Preliminary evidence suggests that PI-9 does indeed possess
an NLS, but it is conformational, comprising a number of noncontiguous
residues (unpublished results). Like many nuclear proteins, PI-9 is
exported from the nucleus via an LMB-sensitive pathway, strongly
implying that it possesses an NES and that the nuclear export receptor
Crm1p (exportin) is involved.
What is the import pathway followed by PI-9? Proteins bearing a
classical NLS bind to importin-
, and translocation requires ATP in
vitro (1, 20). Since PI-9 lacks a classical NLS, it may
not bind importin-
. This is supported by preliminary experiments using established assays in which PI-9 failed to bind to mouse importin-
2 in either the presence or absence of importin-
(unpublished results). However, this conclusion should be qualified by
noting that importin-
now appears to be a member of a larger family of proteins with similar functions and that there is some diversity in
the sequence of signals recognized by importin-
(reviewed in
references 1 and 55). Hence, the formal
possibility that the PI-9 NLS binds a different importin-
family
member cannot be excluded, but it is more likely that PI-9 is imported
in a process that does not require importin-
. Perhaps it binds an importin-
family member directly, as is the case for import of ribosomal proteins and certain transcription factors (20, 42, 55).
PI-9 nuclear import is clearly distinguishable from conventional import
on the basis of its ATP independence in vitro. This nonconventional
mechanism is probably not unique or restricted to particular cell
types, because nuclear import of PI-9 and related ov-serpins occurs in
epithelial, lymphoid, and fibroblast lines. PI-9 does not accumulate in
the nucleus in the presence of CHAPS, so its lower energy requirement
for translocation is not due to retention or anchorage in the nucleus,
as is the case for the unconventional import of nucleoplasmin,
granzymes A and B, and HIV Vpr and Tat (16, 28, 32, 52,
64). Further distinctions between the nonconventional import
pathways utilized by the latter proteins and that utilized by PI-9 are
that import of HIV Vpr does not require cytosolic factors, such as Ran
or importins (32), while the import of Tat requires ATP
hydrolysis but not cytosolic factors (16).
PI-9 apparently exits the nucleus via a conventional process. Its
sensitivity to LMB indicates that egress depends on the factor Crm1p
(exportin), which conventionally recognizes Leu-rich NESs (reviewed in
reference 20). Studies on a number of exported proteins
have led to the definition of a consensus NES, which comprises
LeuXxx(1-3)LeuXxx(2-3)LeuXxxLeu,
but not all sequences conforming to the consensus are functional, and
avid interaction with Crm1p can occur in the absence of a consensus
sequence (20, 24). As shown in Fig.
7, PI-9 has at least two sequences
matching the consensus NES motif. However, the large number of
available serpin crystal structures (66) and the overall
sequence similarity between serpins have allowed us to build a model of
PI-9 with a high degree of certainty based on the crystal structure of
the related serpin, antithrombin (J. Whisstock and P. Bird, unpublished results). This clearly shows that both sequences are buried within the
body of the molecule and would not be available for a protein-protein interaction unless PI-9 is unfolded. As there is no evidence at present
that nuclear export requires unfolding of the passenger protein, this
burying of a potential NES may explain why some sequences that match
the consensus motif are not functional. We suggest that export of PI-9
either involves a linear NES that does not resemble the proposed
consensus sequence or involves a conformational rather than linear NES.
Alternatively, PI-9 may lack an NES altogether but can exit the nucleus
by binding to a protein that possesses a classical NES.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 7.
Potential Leu-rich NESs in PI-9. Shown are two sequences
on PI-9 with similarity to known NESs on Rev (18), Gle1
(36), Rch1 (9), and mitogen-activated protein
kinase kinase (MAPKK) (24). Conserved residues of the NES
are boxed.
|
|
 |
ACKNOWLEDGMENTS |
We thank B. Henderson (Westmead Hospital, Sydney, Australia) for
advice and the RevMAPKK/GFP plasmid, A. Calderone for construction of
the GFP-PAI-2 plasmid, and J. Whisstock (Monash University) for
molecular modeling. We also thank D. Huang (Walter and Eliza Hall
Institute) for Apaf-1 antibodies, E. Remold-O'Donnell (Center for
Blood Research, Boston, Mass.) for MNEI antibodies, J. Wilson and J. Wang (Michigan State University) for LDH antiserum, and D. Pickup (Duke
University Medical Center) for the CrmA cDNA and antiserum.
This work was supported by the National Health and Medical Research
Council of Australia.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Biochemistry and Molecular Biology, P.O. Box 13D, Monash University, Victoria 3800, Australia. Phone: 61 3 9905 3771. Fax: 61 3 9905 4699. E-mail: Phil.Bird{at}med.monash.edu.au.
 |
REFERENCES |
| 1.
|
Adam, S. A.
1999.
Transport pathways of macromolecules between the nucleus and the cytoplasm.
Curr. Opin. Cell Biol.
11:402-406[CrossRef][Medline].
|
| 2.
|
Andersson, S.,
D. L. Davis,
H. Dahlback,
H. Jornvall, and D. W. Russell.
1989.
Cloning, structure, and expression of the mitochondrial cytochrome P-450 sterol 26-hydroxylase, a bile acid biosynthetic enzyme.
J. Biol. Chem.
264:8222-8229[Abstract/Free Full Text].
|
| 3.
|
Annand, R. R.,
J. R. Dahlen,
C. A. Sprecher,
P. de Dreu,
D. C. Foster,
J. A. Mankovich,
R. V. Talanian,
W. Kisiel, and D. A. Giegel.
1999.
Caspase-1(interleukin-1b-converting enzyme) is inhibited by the human serpin analogue proteinase inhibitor 9.
Biochem. J.
342:655-665.
|
| 4.
|
Antalis, T. M.,
M. La Linn,
K. Donnan,
L. Mateo,
J. Gardner,
J. L. Dickinson,
K. Buttigieg, and A. Suhrbier.
1998.
The serine proteinase inhibitor (serpin) plasminogen activation inhibitor type 2 protects against viral cytopathic effects by constitutive interferon alpha/beta priming.
J. Exp. Med.
187:1799-1811[Abstract/Free Full Text].
|
| 5.
|
Belin, D.
1993.
Biology and facultative secretion of plasminogen activator inhibitor-2.
Thromb. Haemostasis
70:144-147[Medline].
|
| 5a.
|
Biggs, J. R.,
J. Yang,
U. Gullberg,
C. Muchardt,
M. Yaniv, and A. S. Kraft.
2001.
The human brm protein is cleaved during apoptosis: the role of cathepsin-G.
Proc. Natl. Acad. Sci. USA
98:3814-3819[Abstract/Free Full Text].
|
| 6.
|
Bird, C. H.,
V. R. Sutton,
J. Sun,
C. E. Hirst,
A. Novak,
J. A. Trapani, and P. I. Bird.
1998.
Selective regulation of apoptosis: the cytotoxic lymphocyte serpin proteinase inhibitor 9 protects against granzyme B-mediated apoptosis without perturbing the Fas cell death pathway.
Mol. Cell. Biol.
18:6387-6398[Abstract/Free Full Text].
|
| 7.
|
Bird, P. I.
1998.
Serpins and regulation of cell death.
Results Probl. Cell Differ.
24:63-89[Medline].
|
| 8.
|
Bird, P. I.
1999.
Regulation of pro-apoptotic leukocyte granule serine proteinases by intracellular serpins.
Immunol. Cell. Biol.
77:47-57[CrossRef][Medline].
|
| 9.
|
Boche, I., and E. Fanning.
1997.
Nucleocytoplasmic recycling of the nuclear localization signal receptor alpha subunit in vivo is dependent on a nuclear export signal, energy and RCC1.
J. Cell Biol.
139:313-325[Abstract/Free Full Text].
|
| 10.
|
Briggs, L. J.,
D. Stein,
J. Goltz,
V. C. Corrigan,
A. Efthymiadis,
S. Hubner, and D. A. Jans.
1998.
The cAMP-dependent protein kinase site (Ser312) enhances dorsal nuclear import through facilitating nuclear localization sequence/importin interaction.
J. Biol. Chem.
273:22745-22752[Abstract/Free Full Text].
|
| 11.
|
Brunk, U. T.,
H. Dalen,
K. Roberg, and H. B. Hellquist.
1997.
Photo-oxidative disruption of lysosomal membranes causes apoptosis of cultured human fibroblasts.
Free Radic. Biol. Med.
23:616-626[CrossRef][Medline].
|
| 11a.
| Buzza, M. S., C. E. Hirst, C. H. Bird, P. Hosking, J. McKendrick, and P. I. Bird. The granzyme B inhibitor, PI-9, is
present in endothelial and mesothelial cells, suggesting it protects
bystander cells during immune responses. Cell Immunol., in press.
|
| 12.
|
Chu, M.,
C. H. Bird,
M. S. Teasdale, and P. I. Bird.
1998.
Turnover of thrombomodulin at the cell surface occurs at a similar rate to receptors that are not actively internalized.
Thromb. Haemostasis
80:119-127[Medline].
|
| 13.
|
Chuang, T. L., and R. R. Schleef.
1999.
Identification of a nuclear targeting domain in the insertion between helices C and D in protease inhibitor-10.
J. Biol. Chem.
274:11194-11198[Abstract/Free Full Text].
|
| 14.
|
Coughlin, P.,
J. Sun,
L. Cerruti,
H. H. Salem, and P. Bird.
1993.
Cloning and molecular characterization of a human intracellular proteinase inhibitor.
Proc. Natl. Acad. Sci. USA
90:9417-9421[Abstract/Free Full Text].
|
| 15.
|
Dickinson, J. L.,
E. J. Bates,
A. Ferrante, and T. M. Antalis.
1995.
Plasminogen activator inhibitor 2 inhibits tumor necrosis factor alpha-induced apoptosis. Evidence for an alternate biological function.
J. Biol. Chem.
270:27894-27904[Abstract/Free Full Text].
|
| 16.
|
Efthymiadis, A.,
L. J. Briggs, and D. A. Jans.
1998.
The HIV-1 Tat nuclear localization sequence confers novel nuclear import properties.
J. Biol. Chem.
273:1623-1628[Abstract/Free Full Text].
|
| 17.
|
Efthymiadis, A.,
H. Shao,
S. Hubner, and D. A. Jans.
1997.
Kinetic characterization of the human retinoblastoma protein bipartite nuclear localization sequence (NLS) in vivo and in vitro. A comparison with the SV40 large T-antigen NLS.
J. Biol. Chem.
272:22134-22139[Abstract/Free Full Text].
|
| 18.
|
Fischer, U.,
J. Huber,
W. C. Boelens,
I. W. Mattaj, and R. Luhrmann.
1995.
The HIV-1 Rev activation domain is a nuclear export signal that accesses an export pathway used by specific cellular RNAs.
Cell
82:475-483[CrossRef][Medline].
|
| 19.
|
Golstein, P.
1974.
Sensitivity of cytotoxic T cells to T-cell mediated cytotoxicity.
Nature
252:81-83[CrossRef][Medline].
|
| 20.
|
Gorlich, D., and U. Kutay.
1999.
Transport between the cell nucleus and the cytoplasm.
Annu. Rev. Cell. Dev. Biol.
15:607-660[CrossRef][Medline].
|
| 21.
|
Grigoryev, S. A.,
J. Bednar, and C. L. Woodcock.
1999.
MENT, a heterochromatin protein that mediates higher order chromatin folding, is a new serpin family member.
J. Biol. Chem.
274:5626-5636[Abstract/Free Full Text].
|
| 22.
|
Harlow, E., and D. Lane.
1988.
Antibodies. A laboratory manual.
Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
|
| 23.
|
Hausmann, G.,
L. A. O'Reilly,
R. van Driel,
J. G. Beaumont,
A. Strasser,
J. A. Adams, and D. C. S. Haung.
2000.
Pro-apoptotic apoptosis protease-activating factor 1 (Apaf-1) has a cytoplasmic localization distinct from Bcl-2 or Bcl-xL.
J. Cell Biol.
149:623-633[Abstract/Free Full Text].
|
| 24.
|
Henderson, B. R., and A. Eleftheriou.
2000.
A comparison of the activity, sequence specificity, and CRM1-dependence of different nuclear export signals.
Exp. Cell Res.
256:213-224[CrossRef][Medline].
|
| 25.
|
Hood, J. K., and P. A. Silver.
1999.
In or out? Regulating nuclear transport.
Curr. Opin. Cell Biol.
11:241-247[CrossRef][Medline].
|
| 26.
|
Hubner, S.,
C. Y. Xiao, and D. A. Jans.
1997.
The protein kinase CK2 site (Ser111/112) enhances recognition of the simian virus 40 large T-antigen nuclear localization sequence by importin.
J. Biol. Chem.
272:17191-17195[Abstract/Free Full Text].
|
| 27.
|
Huntington, J. A.,
R. A. Read, and R. W. Carrell.
2000.
Structure of a serpin-protease complex shows inhibition by deformation.
Nature
407:923-926[CrossRef][Medline].
|
| 28.
|
Jans, D. A.,
L. J. Briggs,
P. Jans,
C. J. Froelich,
G. Parasivam,
S. Kumar,
V. R. Sutton, and J. A. Trapani.
1998.
Nuclear targeting of the serine proteinase granzyme A (fragmentin-1).
J. Cell Sci.
111:2645-2654[Abstract].
|
| 29.
|
Jans, D. A.,
M. J. Ackermann,
J. R. Bischoff,
D. H. Beach, and R. Peters.
1991.
p34cdc2-mediated phosphorylation at T124 inhibits nuclear import of SV-40 T antigen proteins.
J. Cell Biol.
115:1203-1212[Abstract/Free Full Text].
|
| 30.
|
Jans, D. A., and P. Jans.
1994.
Negative charge at the casein kinase II site flanking the nuclear localization signal of the SV40 large T-antigen is mechanistically important for enhanced nuclear transport.
Oncogene
9:2961-2968[Medline].
|
| 31.
|
Jans, D. A.,
P. Jans,
L. J. Briggs,
V. Sutton, and J. A. Trapani.
1996.
Nuclear transport of granzyme B (fragmentin 2).
J. Biol. Chem.
271:30781-30789[Abstract/Free Full Text].
|
| 32.
|
Jenkins, Y.,
M. McEntee,
K. Weis, and W. C. Greene.
1998.
Characterization of HIV-1 Vpr nuclear import: analysis of signals and pathways.
J. Cell Biol.
143:875-885[Abstract/Free Full Text].
|
| 33.
|
Kranz, D. M., and H. N. Eisen.
1987.
Resistance of cytotoxic lymphocytes to lysis by a clone of cytotoxic T lymphocytes.
Proc. Natl. Acad. Sci. USA
84:3375-3379[Abstract/Free Full Text].
|
| 34.
|
Madison, E. L., and P. Bird.
1992.
A vector, pSHT, for the expression and secretion of protein domains in mammalian cells.
Gene
121:179-180[CrossRef][Medline].
|
| 35.
|
Miyata, T.,
M. Nangaku,
D. Suzuki,
R. Inagi,
K. Uragami,
H. Sakai,
K. Okubo, and K. Kurokawa.
1998.
A mesangium-predominant gene, megsin, is a new serpin upregulated in IgA nephropathy.
J. Clin. Investig.
120:828-836.
|
| 36.
|
Murphy, R., and S. R. Wente.
1996.
An RNA-export mediator with an essential nuclear export signal.
Nature
383:357-360[CrossRef][Medline].
|
| 37.
|
Nagata, S.
1997.
Apoptosis by death factor.
Cell
88:355-365[CrossRef][Medline].
|
| 38.
|
Nagler-Anderson, C.,
C. R. Verret,
A. A. Firmenich,
M. Berne, and H. N. Eisen.
1988.
Resistance of primary CD8+ cytotoxic T lymphocytes to lysis by cytotoxic granules from cloned T cell lines.
J. Immunol.
141:3299-3305[Abstract].
|
| 39.
|
Nigg, E. A.
1997.
Nucleocytoplasmic transport: signals, mechanisms and regulation.
Nature
386:779-787[CrossRef][Medline].
|
| 40.
|
Ochs, R.,
M. Lischwe,
P. O'Leary, and H. Busch.
1983.
Localization of nucleolar phosphoproteins B23 and C23 during mitosis.
Exp. Cell Res.
46:139-149.
|
| 41.
|
Ooms, L.,
J. Nicholl,
P. Bird, and G. R. Sutherland.
1995.
Localization of the human monocyte/neutrophil elastase inhibitor gene to chromosome 6p25.
Chromosome Res.
3:447[CrossRef].
|
| 42.
|
Pemberton, L. F.,
J. S. Rosenblum, and G. Blobel.
1999.
Nuclear import of the TATa-binding protein: mediation by the karyopherin Kap114p and a possible mechanism for intranuclear targeting.
J. Cell Biol.
145:1407-1417[Abstract/Free Full Text].
|
| 43.
|
Perkins, A.,
A. W. Cochrane,
S. M. Ruben, and C. A. Rosen.
1989.
Structural and functional characterization of the human immunodeficiency virus rev protein.
J. Acquir. Immune Defic. Syndr.
2:256-263.
|
| 44.
|
Potempa, J.,
E. Korzus, and J. Travis.
1994.
The serpin superfamily of proteinase inhibitors: structure, function and regulation.
J. Biol. Chem.
269:15957-15960[Free Full Text].
|
| 45.
|
Remold-O'Donnell, E.
1993.
The ovalbumin family of serpin proteins.
FEBS Lett.
315:105-108[CrossRef][Medline].
|
| 46.
|
Rihs, H. P., and R. Peters.
1989.
Nuclear transport kinetics depend on phosphorylation-site-containing sequences flanking the karyophilic signal of the simian virus 40 T-antigen.
EMBO J.
8:1479-1484[Medline].
|
| 47.
|
Schick, C.,
Y. Kamachi,
A. J. Bartuski,
S. Cataltepe,
N. M. Schechter,
P. A. Pemberton, and G. A. Silverman.
1997.
Squamous cell carcinoma antigen 2 is a novel serpin that inhibits the chymotrypsin-like proteinases cathepsin G and mast cell chymase.
J. Biol. Chem.
272:1849-1855[Abstract/Free Full Text].
|
| 48.
| |